Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.17 Analyst target: $13.75 Upside: 165.96%
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
See the full interactive analysis & chart →Informational only — not investment advice.